Journal of Personalised Medecine
by Laura Maintz
1,2,*,† [ORCID] , Thomas Bieber
1,2,3,†, Helen D. Simpson
4 and Anne-Laure Demessant-Flavigny
5 [ORCID]
1 Department of Dermatology and Allergy, University Hospital Bonn, 53127 Bonn, Germany
2 Christine Kühne Center for Allergy Research and Education Davos (CK-CARE), 7265 Davos, Switzerland
3 Davos Biosciences, Herman-Burchard-Str. 9, CH-7265 Davos Wolfgang, Switzerland
4 My Word Medical Writing, 13260 Cassis, France
5 La Roche-Posay International, 92300 Levallois-Perret, France*
Author to whom correspondence should be addressed.
†These authors contributed equally to this work.
J. Pers. Med. 2022, 12(6), 893; https://doi.org/10.3390/jpm12060893
Submission received: 15 April 2022 / Revised: 20 May 2022 / Accepted: 24 May 2022 / Published: 28 May 2022
Atopic dermatitis (AD) affects up to 20% of children and is considered the starting point of the atopic march with the development of food allergy, asthma, and allergic rhinitis. The heterogeneous phenotype reflects distinct and/or overlapping pathogenetic mechanisms with varying degrees of epidermal barrier disruption, activation of different T cell subsets and dysbiosis of the skin microbiome. Here, we review current evidence suggesting a systemic impact of the cutaneous inflammation in AD together with a higher risk of asthma and other comorbidities, especially in severe and persistent AD.
Dear Readers, The Skinobs team would like to apologise sincerely to Faiza Hussain, Co-Founder and…
Acheless is an essential wearable device for modern society, where digital living is commonplace. To…
Linking consumer data with sensory data is an essential step in formulating products that accurately…